Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials

Standard-dose intravenous recombinant interleukin-2 (rIL-2) is indicated for the treatment of some subtypes of cancer; however, severe adverse events, including venous thromboembolism (VTE), may complicate its administration. Low-dose subcutaneous rIL-2 is being studied for the management of immune-...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmoudpour, Seyed Hamidreza, Jankowski, Marius, Valerio, Luca, Becker, Christian, Espinola-Klein, Christine, Konstantinides, Stavros, Quitzau, Kurt, Barco, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509335/
https://www.ncbi.nlm.nih.gov/pubmed/31073219
http://dx.doi.org/10.1038/s41598-019-43530-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509335/
https://www.ncbi.nlm.nih.gov/pubmed/31073219
http://dx.doi.org/10.1038/s41598-019-43530-x

Ejemplares similares